The oral anti-fibrotic treatment Ofev (nintedanib) was found to be generally well-tolerated among children and adolescents with fibrosing interstitial…
Articles by Marisa Wexler, MS
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to EI-1071, an oral anti-inflammatory that Elixiron Immunotherapeutics…
The U.S. Food and Drug Administration (FDA) has given fast-track designation to DWN12088, an experimental anti-fibrotic medication that Daewoong…
Most idiopathic pulmonary fibrosis (IPF) patients treated with NP-120 (ifenprodil) in a 12-week clinical trial saw their lung function improve…
The Pulmonary Fibrosis Foundation (PFF) is hosting its sixth annual PFF Walk fundraiser with virtual and in-person events over…
The experimental oral therapy PLN-74809 was overall well tolerated in people with idiopathic pulmonary fibrosis (IPF) participating in the…
PureTech has initiated a clinical study to evaluate the safety and effectiveness of its experimental therapy LYT-100 in people…
Algernon Pharmaceuticals has secured a patent in Canada covering the use of NP-120 (ifenprodil) as a treatment for idiopathic…
The U.S. Food and Drug Administration (FDA) has given Daewoong Pharmaceutical the go-ahead to start a Phase 2 clinical…
Participants in a Phase 2 trial testing Algernon Pharmaceuticals’ NP-120 (ifenprodil) in people with chronic cough associated with idiopathic…